Revumenib：急性白血病治疗的新时代。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-02-01 Epub Date: 2025-01-24 DOI:10.1016/j.trecan.2025.01.006

David A Martínez-Gamboa, Justin Kaner

{"title":"Revumenib：急性白血病治疗的新时代。","authors":"David A Martínez-Gamboa, Justin Kaner","doi":"10.1016/j.trecan.2025.01.006","DOIUrl":null,"url":null,"abstract":"The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"81-83"},"PeriodicalIF":14.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Revumenib: a new era in acute leukemia treatment.\",\"authors\":\"David A Martínez-Gamboa, Justin Kaner\",\"doi\":\"10.1016/j.trecan.2025.01.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"81-83\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2025.01.006\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.01.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

AUGMENT-101临床试验报告称，revumenib的使用改善了急性白血病患者的总生存期（OS）和完全缓解(CR)/CR及部分血液学恢复（CRh），并发布了更新的数据，对2期结果进行了更长时间的随访。此外，revumenib已获得FDA批准用于复发或难治性（r/r）赖氨酸甲基转移酶2A重排（KMT2A-r）急性白血病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Revumenib: a new era in acute leukemia treatment.

The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.